大剂量参附注射液治疗顽固性心力衰竭的临床观察

The Clinical Observation of High-dose of Shenfu Injection in Treating the Refactory Heart Failure

目的观察大剂量参附注射液治疗顽固性心力衰竭(RHF)的临床疗效。方法将本院ICU的RHF患者60例随机分为对照组和治疗组各30例,两组均给予常规抗心力衰竭治疗,治疗组加用参附注射液静滴,疗程14 d。结果治疗组的综合疗效与证候疗效总有效率分别为76.67%、83.33%,均优于对照组的60.00%、63.33%(P<0.05或P<0.01);两组治疗后心脏监测指标均有改善(P<0.05),而治疗组改善程度优于对照组(P<0.05或P<0.01)。结论大剂量参附注射液能够提高RHF的临床疗效。

Objective： To observe the clinical efficacy of high doses of Shenfu Injection in treating the refactory heart failure. Methods： Sixty patients of RHF in ICU of our hospital was divided into two groups randomly： the treatment group and the control group ,30 patients in each group. Two groups got the conventional treatment of heart failure. However,the patients of the treatment group got the Shenfu Injection of static drops at the same time. The period of treatment lasted for 14 d. Results： The total effective rate of the comprehensive curative effect and the symptom curative effect in the treatment group were 76.67% and 83.33% respectively,better than that of of the control group whose effective rate were 60.00% and 63.33% respectively. The index of cardiac monitoring, such as LEVF, CO and BNP were improved in both groups after treatment. However,the treatment group has a better improvement. Conclusion： High doses of Shenfu Injection is able to raise the clinical curative effect of RHF.